TITLE

Rationale for the Use of Aldosterone Antagonists in Congestive Heart Failure

AUTHOR(S)
Rocha, R.; Williams, G.H.
PUB. DATE
March 2002
SOURCE
Drugs;2002, Vol. 62 Issue 5, p723
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Traditionally, the role of aldosterone in heart failure was thought to be a result of its effects on epithelial cells where it induces sodium reabsorption and potassium excretion with subsequent haemodynamic effects from intravascular volume expansion. On this basis, spironolactone, a non-selective aldosterone antagonist, has been used for the treatment of congestive heart failure to block aldosterone-mediated effects in epithelial cells. The Randomized Aldactone Evaluation Study (RALES), in which spironolactone was added to existing therapy in patients with heart failure, showed a significant reduction in morbidity and mortality. These results suggest that the role of aldosterone in the pathophysiology of cardiovascular disease may be more complex than previously recognised. There now is extensive experimental and growing clinical evidence for an important physiological role for aldosterone in the pathology of cardiac and renal disease. Classical effects of aldosterone are mediated via its nuclear receptor. Novel non-epithelial effects of aldosterone are mediated via a second messenger system, which involves activation of the sodium/hydrogen antiporter. These effects of aldosterone have been demonstrated in the kidney, vascular smooth muscle cell and leukocytes, and in the regulation of rapid corticotropin suppression. It has been hypothesised that cardiac damage induced by aldosterone is independent of the presence of hypertension. In support of this, experimental evidence demonstrates that cardiovascular damage induced by aldosterone can be prevented by administration of a selective mineralocorticoid receptor antagonist. These findings suggest the dissociation between cardiovascular lesions and high blood pressure, and highlight the importance of aldosterone in the pathological changes.
ACCESSION #
6374040

 

Related Articles

  • Aldosteronism in Hypertension. Spark, Richard F.; Melby, James C. // Annals of Internal Medicine;Oct68, Vol. 69 Issue 4, p685 

    Deals with a study which examined the effectiveness of the pharmacologic blockade spironolactone in reducing excess endogenous aldosterone. Materials and methods; Results; Discussion.

  • Aldosterone Receptor Antagonists for Hypertension: What Do They Offer? Liew, Danny; Krum, Henry // Drugs;2003, Vol. 63 Issue 19, p1963 

    Aldosterone is an important and independent target for therapeutic intervention in hypertension and hypertension-related diseases. Its actions, once thought to be limited to the distal convoluted tubule of the kidney, are now recognised to be wide-ranging, including interactions with...

  • Spironolactone: severe heart failure cut by one-third.  // WHO Drug Information;1999, Vol. 13 Issue 3, p153 

    Shows that adding spironolactone, an aldosterone receptor antagonist, to standard therapy for severe heart failure can reduce the risk of death and hospitalization. Ability of aldosterone receptor to prevent progressive heart failure; Increasing prevalence of heart failure and the high burden...

  • Stimulation of Xenopus oocyte Na+,K+ATPase by the serum and glucocorticoid-dependent kinase sgk1. Setiawan, Iwan; Henke, Guido; Feng, Yuxi; Böhmer, Christoph; Vasilets, Larisa A.; Schwarz, Wolfgang; Lang, Florian // Pflugers Archiv European Journal of Physiology;Jun2002, Vol. 444 Issue 3, p426 

    The serum and glucocorticoid-dependent kinase-1 (sgk1) is expressed in a wide variety of tissues including renal epithelial cells. As it is up-regulated by aldosterone, it is considered to participate in the regulation of renal Na+ reabsorption. Indeed, co-expression of sgk1 with the renal...

  • Liddle's Syndrome.  // Encyclopedic Reference of Molecular Pharmacology;2004, p555 

    A definition of the term "Liddle's syndrome" is presented. It refers to an autosomal dominant disorder that is caused by persistent hyperactivity of the epithelial Na channel. The disease is characterized by early onset arterial hypertension, hypokalemia and metabolic alkalosis. Its symptoms...

  • Review of aldosterone- and angiotensin II-induced target organ damage and prevention Struthers, Allan D.; MacDonald, Thomas M. // Cardiovascular Research;Mar2004, Vol. 61 Issue 4, p663 

    Aldosterone is well recognized as a cause of sodium reabsorption, water retention, and potassium and magnesium loss; however, it also produces a variety of other actions that lead to progressive target organ damage in the heart, vasculature, and kidneys. Aldosterone interacts with...

  • Primary aldosteronism and aldosterone-associated hypertension. Rayner, B. // Journal of Clinical Pathology;Jul2008, Vol. 61 Issue 7, p825 

    The field of primary aldosteronism (PA) and aldosterone-related hypertension has undergone rapid evolution. From a relatively rare curiosity PA has become a common problem particularly in selected hypertensive populations. Patients with PA and aldosterone-related hypertension appear to be at...

  • Primary Aldosteronism Due to an Adrenal Carcinoma. Crane, Milton G.; Harris, John J.; Herber, Raymond // Annals of Internal Medicine;Sep65, Vol. 63 Issue 3, p494 

    Describes a patient with primary aldosteronism caused by an adrenocortical carcinoma. Effect of spironolactone on blood pressure, body weight and electrolytes; Rate of urinary aldosterone excretion; Secretion rate of deoxycorticosterone.

  • Spironolactone treatment in patients with diabetic microalbuminuria and resistant hypertension. Kota, Sunil; Jammula, Sruti; Kota, Siva; Meher, Lalit; Modi, Kirtikumar // International Journal of Diabetes in Developing Countries;Jan-Mar2012, Vol. 32 Issue 1, p33 

    Resistant hypertension is common in diabetes. Spironolactone by inhibiting aldosterone not only exerts antihypertensive effect but also antiproteinuric effect. In this study, the mean decrease in systolic and diastolic blood pressure after 4 weeks of spironolactone was 25.5 ± 7.8 and 11.4...

Share

Read the Article

Courtesy of NEW JERSEY STATE LIBRARY

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics